Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cancer Center of Kansas - Wichita
Wichita, Kansas, United States
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
- Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, United States
- State University of New York Upstate Medical University
Syracuse, New York, United States
- Mcleod Regional Medical Center
Florence, South Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Aug 2020
- Primary completion
- 9 Feb 2022
- Completion
- 9 Feb 2022
- Last update posted
- 15 Jun 2022
- Registered enrollment
- 0
- Registry id
- NCT03841565
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.